Lyell Immunopharma VP sells shares for tax withholding

Lyell Immunopharma, Inc. officer Veronica Sanchez Bulis, VP and Corporate Controller, reported a sale of 621 shares of common stock on 2026-08-10 at a weighted average price of $14.34 per share, with sale prices ranging from $14.20 to $14.34.

Rhea-AI Filing Summary

Lyell Immunopharma, Inc. officer Veronica Sanchez Bulis, VP and Corporate Controller, reported a sale of 621 shares of common stock on 2026-08-10 at a weighted average price of $14.34 per share, with sale prices ranging from $14.20 to $14.34. According to the disclosure, the shares were automatically sold to cover tax withholding obligations arising from the settlement of vested restricted stock units, rather than as a discretionary open-market sale. Following this transaction, Bulis directly holds 14,799 shares of Lyell Immunopharma common stock.

Insider Trade Summary

Net Seller: 621 shares

Net Sell 1 txn

Insider Bulis Veronica Sanchez

Role VP, Corporate Controller

Sold 621 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	621	$14.34	$9K

Holdings After Transaction: Common Stock — 14,799 shares (Direct)

Footnotes (2)

1. F1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
2. F2. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Key Figures

Shares sold: 621 shares Weighted average sale price: $14.34 per share Sale price range: $14.20 to $14.34 per share +1 more

4 metrics

Shares sold 621 shares Common stock sold on 2026-08-10 to cover tax withholding

Weighted average sale price $14.34 per share Weighted average price for shares sold on 2026-08-10

Sale price range $14.20 to $14.34 per share Range of prices for the 621 shares sold

Shares owned after transaction 14,799 shares Direct ownership of Veronica Sanchez Bulis after the sale

Key Terms

weighted average price, tax withholding obligation, restricted stock units

3 terms

weighted average price financial

"The price reported above reflects the weighted average price of the shares sold."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligation financial

"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."

restricted stock units financial

"tax withholding obligation from settlement of vested restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lyell Immunopharma (LYEL) report for Veronica Sanchez Bulis?

Lyell Immunopharma reported that Veronica Sanchez Bulis, VP and Corporate Controller, sold 621 shares of common stock on 2026-08-10. The disclosure states this sale was to cover tax withholding from vested restricted stock units.

At what price were the LYEL shares sold in Veronica Sanchez Bulis’s Form 4 filing?

The shares were sold at a weighted average price of $14.34 per share, with individual sale prices ranging from $14.20 to $14.34. The reporting person will provide details of each sale price within this range upon request.

How many Lyell Immunopharma (LYEL) shares does Veronica Sanchez Bulis hold after the reported sale?

After the reported transaction, Veronica Sanchez Bulis directly holds 14,799 shares of Lyell Immunopharma common stock. This figure reflects her post-transaction ownership as disclosed in the Form 4 filing.

Why were Veronica Sanchez Bulis’s LYEL shares sold according to the Form 4 footnotes?

The footnotes state the 621 shares were automatically sold to satisfy the tax withholding obligation from the settlement of vested restricted stock units, indicating a tax-related transaction rather than a discretionary sale.

Was the LYEL insider sale by Veronica Sanchez Bulis under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as using a plan, and the footnotes do not reference any such plan. The sale is described instead as covering tax withholding from restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 04:22 PM Accepted by SEC EDGAR 08/11/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bulis Veronica Sanchez

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY, SUITE 101

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Corporate Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S		621(1)	D	$14.34(2)	14,799	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

2. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.20 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

	/s/ Mark Meltz, Attorney-in-Fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)